vTv Therapeutics, with its focus on developing treatments for diabetes and inflammatory diseases, has shown potential in its clinical trials, particularly with its lead compound, TTP399, for type 1 diabetes, which is in a phase 3 trial. Given the recent positive outcomes and the anticipation of further clinical results, there is a potential investment opportunity.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, is actively engaged in the development of orally administered treatments for diabetes and other chronic diseases. Their lead product, TTP399, has shown promising results in clinical trials for the treatment of type 1 diabetes and is currently in phase 3. The company's strategic focus and recent advancements in their clinical programs suggest potential upcoming catalysts that could significantly impact the company's valuation and stock price. With their strong insider ownership and recent positive trial results, vTv Therapeutics presents a compelling case for investors looking for exposure in the biopharmaceutical sector. Additionally, the market for diabetes treatment continues to grow, providing a favorable backdrop for vTv Therapeutics' targeted therapies. Investors should closely monitor the progress of the phase 3 trials and any regulatory updates that could serve as significant price catalysts.